AdaptHealth
AHCO · NYSE · Healthcare · United States
Financials at a glance
Source: SEC XBRLAnnual
Quarterly · last 8
Revenue (FY2025)
$3.2B
Net margin
-2.2%
ROE
-4.7%
Revenue CAGR (2y)
+0.7%
EPS (FY2025)
-0.52
Net profit (FY2025)
$-70.8M
Ask MarketChacha about AHCO
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Why it moved
- Aug 4, 2026
AdaptHealth shares plunged after its Q2 2026 earnings release showed a large goodwill impairment driving a net loss, alongside a sharp cut to full-year 2026 Adjusted EBITDA guidance (to $490–520M from prior $680–730M) due to discontinued operations, contract impacts, and other factors.
- Jul 29, 2026
No company-specific catalyst or filing today; AHCO fell with the broader market or healthcare sector after recent positive coverage of its diabetes unit divestiture.
· confidence: low - Jul 27, 2026
AHCO rose on continued positive sentiment from its July 20 announcement of a $235M cash sale of its diabetes health business to Cardinal Health (via 8-K material agreement), which allows focus on core sleep/respiratory operations; analysts at Jefferies and Truist upgraded or reiterated Buy ratings shortly after.
- Jul 23, 2026
No clear company-specific catalyst explains the decline; the diabetes business sale to Cardinal Health drew positive analyst notes earlier in the week and the latest 8-K was a material agreement filed July 20.
Daily moves with the verified reason behind them. Education only — not investment advice.
Financials
Yearly
| Period | Revenue | Net profit | EPS | Net margin | ROE |
|---|---|---|---|---|---|
| FY2025 | $3.2B | $-70.8M | -0.52 | -2.2% | -4.7% |
| FY2024 | $3.3B | $90.4M | 0.61 | 2.8% | 5.8% |
| FY2023 | $3.2B | $-678.9M | -5.31 | -21.2% | -46.5% |
Quarterly
| Period | Revenue | Net profit | EPS | Net margin |
|---|---|---|---|---|
| 2026Q2 | $740.3M | $-133.9M | -0.99 | -18.1% |
| 2026Q1 | $819.8M | $-16.0M | -0.12 | -2.0% |
| 2025Q3 | $820.3M | $24.5M | 0.16 | 3.0% |
| 2025Q2 | $657.1M | $14.7M | 0.10 | 2.2% |
| 2025Q1 | $777.9M | $-7.2M | -0.05 | -0.9% |
| 2024Q3 | $805.9M | $22.9M | 0.15 | 2.8% |
| 2024Q2 | $806.0M | $19.4M | 0.13 | 2.4% |
| 2024Q1 | $792.5M | $-2.1M | -0.02 | -0.3% |
| 2023Q3 | $804.0M | $-454.1M | -3.43 | -56.5% |
| 2023Q2 | $793.3M | $14.0M | 0.09 | 1.8% |
| 2023Q1 | $744.6M | $15.7M | -0.06 | 2.1% |
Figures as reported, in reporting currency. Source: SEC XBRL.
Filings & announcements
2026
- SEC8/4/2026
- SEC8/4/2026material
- SEC7/20/2026material
- SEC7/7/2026material
- SEC7/2/2026material
- SEC6/22/2026material
- SEC6/2/2026
- SEC5/5/2026material
- SEC5/5/2026
- SEC2/24/2026material
- SEC2/24/2026
2025
- SEC11/4/2025material
- SEC11/4/2025
- SEC8/5/2025material
- SEC8/5/2025material
- SEC8/5/2025
In the news
- Adapthealth director Dale Wolf buys $244,600 in company stockInvesting.com India · 8/11/2026
- Adapthealth director Kenneth Samet buys $149,930 in shares By Investing.comInvesting.com Australia · 8/11/2026
- AdaptHealth (NASDAQ:AHCO) Director Purchases $149,930.00 in StockMarketBeat · 8/11/2026
- AdaptHealth (NASDAQ:AHCO) Reaches New 52-Week Low - What's Next?MarketBeat · 8/10/2026
- Why AdaptHealth Stock Plummeted This WeekThe Motley Fool · 8/9/2026
- AdaptHealth (AHCO) Reports A Net Loss And Goodwill Impairment, Is The Stock A Bargain?simplywall.st · 8/8/2026
- AdaptHealth (NASDAQ:AHCO) Downgraded by Wall Street Zen to HoldMarketBeat · 8/8/2026
- AdaptHealth Corp. $AHCO Shares Sold by Royal Bank of CanadaMarketBeat · 8/7/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.